Malignant mesothelioma: Development to therapy

Journal of Cellular Biochemistry

Volumn 115, Issue 1, 2014, Pages 1-7

  Thompson, Joyce K ^a   Westbom, Catherine M ^a   Shukla, Arti ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

ASBESTOS; INFLAMMATION; MALIGNANT MESOTHELIOMA; MESOTHELIUM

Indexed keywords

ASBESTOS; BEVACIZUMAB; BORTEZOMIB; CISPLATIN; DOXORUBICIN; EPHRIN RECEPTOR B4 INHIBITOR; MESOTHELIN; PEMETREXED; PODOPLANIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; HUMAN; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MESOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL;

ASBESTOS; INFLAMMATION; MALIGNANT MESOTHELIOMA; MESOTHELIUM;

ASBESTOS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULAR TARGETED THERAPY;

EID: 84887902261     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24642     Document Type: Article

References (60)

1. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y,. 2013. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 190 (12): 6239-6249.
2. Allen TC,. 2013. Accurate diagnosis of mesothelioma: More important than ever. Arch Pathol Lab Med 137 (5): 601-602.
3. Bolukbas S, Eberlein M, Fisseler-Eckhoff A, Schirren J,. 2013. Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: The outcome of incomplete resections. Lung Cancer 81 (2): 241-246.
4. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M,. 2011. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43 (7): 668-672.
5. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, Baris YI,. 2007. A mesothelioma epidemic in Cappadocia: Scientific developments and unexpected social outcomes. Nat Rev Cancer 7 (2): 147-154.
6. Cugell DW, Kamp DW,. 2004. Asbestos and the pleura: A review. Chest 125 (3): 1103-1117.
7. Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL,. 2012. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer 77 (3): 567-571.
8. Felten MK, Khatab K, Knoll L, Schettgen T, Muller-Berndorff H, Kraus T,. 2013. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Int Arch Occup Environ Health.
9. Filiberti R, Parodi S, Libener R, Ivaldi GP, Canessa PA, Ugolini D, Bobbio B, Marroni P,. 2013. Diagnostic value of mesothelin in pleural fluids: Comparison with CYFRA 21-1. and CEA. Med Oncol 30 (2): 543.
10. Gazdar AF, Carbone M,. 2003. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 5 (3): 177-181.
11. Giltay R, Timpl R, Kostka G,. 1999. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol 18 (5): 469-480.
12. Guthrie GD, Jr, Mossman BT, editor. 1993. Health effects of mineral dusts, reviews in mineralogy, Vol. 28 (Series editor: Paul H. Ribbe), Washington, D.C.: Mineralogical Society of America. pp. 1-584.
13. Hartung F, Weber GF,. 2013. RNA blood levels of osteopontin splice variants are cancer markers. SpringerPlus 2 (1): 110.
14. Hassan R, Bera T, Pastan I,. 2004. Mesothelin: A new target for immunotherapy. Clin Cancer Res 10 (12 Pt 1): 3937-3942.
15. Hazarika M, White RM, Johnson JR, Pazdur R,. 2004. FDA drug approval summaries: Pemetrexed (Alimta). Oncologist 9 (5): 482-488.
16. Heintz NH, Janssen-Heininger YM, Mossman BT,. 2010. Asbestos, lung cancers, and mesotheliomas: From molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 42 (2): 133-139.
17. Henzi T, Blum WV, Pfefferli M, Kawecki TJ, Salicio V, Schwaller B,. 2009. SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. Am J Pathol 174 (6): 2324-2336.
18. Hillegass JM, Shukla A, MacPherson MB, Lathrop SA, Alexeeva V, Perkins TN, van der Vliet A, Vacek PM, Gunter ME, Mossman BT,. 2010. Mechanisms of oxidative stress and alterations in gene expression by Libby six-mix in human mesothelial cells. Part Fibre Toxicol 7: 26.
19. Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP,. 2010. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 181 (6): 620-625.
20. Jones LM, Gardner MJ, Catterall JB, Turner GA,. 1995. Hyaluronic acid secreted by mesothelial cells: A natural barrier to ovarian cancer cell adhesion. Clin Exp Metastasis 13 (5): 373-380.
21. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, Pass HI, Gaudino G, Carbone M, Yang H,. 2012. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 72 (13): 3290-3301.
22. Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmuller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P,. 2013. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther 12 (6): 1073-1084.
23. Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V,. 2013. EphB4 as a therapeutic target in mesothelioma. BMC Cancer 13: 269.
24. Macura SL, Hillegass JM, Steinbacher JL, MacPherson MB, Shukla A, Beuschel SL, Perkins TN, Butnor KJ, Lathrop MJ, Sayan M, Hekmatyar K, Taatjes DJ, Kauppinen RA, Landry CC, Mossman BT,. 2012. A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas. J Histochem Cytochem 60 (9): 658-674.
25. Miyoshi S, Hamada H, Hamaguchi N, Kato A, Katayama H, Irifune K, Ito R, Miyazaki T, Okura T, Higaki J,. 2012. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo. Int J Oncol 41 (2): 449-456.
26. Moalli PA, MacDonald JL, Goodglick LA, Kane AB,. 1987. Acute injury and regeneration of the mesothelium in response to asbestos fibers. Am J Pathol 128 (3): 426-445.
27. Mossman BT, Bignon J, Corn M, Seaton A, Gee JB,. 1990. Asbestos: Scientific developments and implications for public policy. Science 247 (4940): 294-301.
28. Mossman BT, Lippmann M, Hesterberg TW, Kelsey KT, Barchowsky A, Bonner JC,. 2011. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev 14 (1-4): 76-121.
29. Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R,. 2013. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 182 (4): 1065-1077.
30. Mutsaers SE,. 2004. The mesothelial cell. Int J Biochem Cell Biol 36 (1): 9-16.
31. Myojin T, Azuma K, Okumura J, Uchiyama I,. 2012. Future trends of mesothelioma mortality in Japan based on a risk function. Ind Health 50 (3): 197-204.
32. Nymark P, Lindholm PM, Korpela MV, Lahti L, Ruosaari S, Kaski S, Hollmen J, Anttila S, Kinnula VL, Knuutila S,. 2007. Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genomics 8. doi:10.1186/1471-2164-8-62
33. O'Brien ME, Gaafar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A, Hasan B, Van Meerbeeck JP, Baas P,. 2013. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). Eur J Cancer 49 (13): 2815-2822.
34. Pantazopoulos I, Boura P, Xanthos T, Syrigos K,. 2013. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J 41 (3): 706-715.
35. Pass HI, Carbone M,. 2009. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 21 (2): 97-104.
36. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C,. 2012. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367 (15): 1417-1427.
37. Robinson BW, Musk AW, Lake RA,. 2005. Malignant mesothelioma. Lancet 366 (9483): 397-408.
38. Shukla A, Gulumian M, Hei TK, Kamp D, Rahman Q, Mossman BT,. 2003. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med 34 (9): 1117-1129.
39. Shukla A, MacPherson MB, Hillegass J, Ramos-Nino ME, Alexeeva V, Vacek PM, Bond JP, Pass HI, Steele C, Mossman BT,. 2009a. Alterations in gene expression in human mesothelial cells correlate with mineral pathogenicity. Am J Respir Cell Mol Biol 41 (1): 114-123.
40. Shukla A, Bosenberg MW, MacPherson MB, Butnor KJ, Heintz NH, Pass HI, Carbone M, Testa JR, Mossman BT,. 2009b. Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis. Am J Pathol 175 (5): 2197-2206.
41. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT,. 2010. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer 9: 314.
42. Shukla A, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, O'Byrne KJ, Testa JR, Pass HI, Faux SP, Mossman BT,. 2011. An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. Am J Respir Cell Mol Biol 45 (5): 906-914.
43. Shukla A, Miller JM, Cason C, Sayan M, MacPherson MB, Beuschel SL, Hillegass J, Vacek PM, Pass HI, Mossman BT,. 2013. Extracellular signal-regulated kinase 5: A potential therapeutic target for malignant mesotheliomas. Clin Cancer Res 19 (8): 2071-2083.
44. Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, Ho M,. 2013. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther 12 (4): 416-426.
45. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M,. 2011. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43 (10): 1022-1025.
46. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED,. 2008. US mesothelioma patterns 1973-2002: Indicators of change and insights into background rates. Eur J Cancer Prev 17 (6): 525-534.
47. Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ,. 2009. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study. J Thorac Cardiovasc Surg 138 (2): 405-411.
48. Vogelzang NJ,. 2005. Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer 50 (Suppl 1): S23-S24.
49. Wagner JC, Sleggs CA, Marchand P,. 1960. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17: 260-271.
50. Wang KX, Denhardt DT,. 2008. Osteopontin: Role in immune regulation and stress responses. Cytokine Growth Factor Rev 19 (5-6): 333-345.
51. Wang H, Gillis A, Zhao C, Lee E, Wu J, Zhang F, Ye F, Zhang DY,. 2011. Crocidolite asbestos-induced signal pathway dysregulation in mesothelial cells. Mutat Res 723 (2): 171-176.
52. Wang K, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I,. 2012. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS ONE 7 (4): e33214.
53. Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I,. 2013. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther 12 (1): 48-57.
54. World Health Organization. 2012. History of fighting against the toxic substance, asbestos. Available from: http://www.asbestos.com/asbestos/who.php. Accessed on November 26, 2012.
55. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS,. 2005. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res 11 (12): 4305-4315.
56. Xu J, Futakuchi M, Shimizu H, Alexander DB, Yanagihara K, Fukamachi K, Suzui M, Kanno J, Hirose A, Ogata A, Sakamoto Y, Nakae D, Omori T, Tsuda H,. 2012. Multi-walled carbon nanotubes translocate into the pleural cavity and induce visceral mesothelial proliferation in rats. Cancer Sci 103 (12): 2045-2050.
57. Yamaki E, Yajima T, Kosaka T, Mogi A, Tanaka S, Kuwano H,. 2013. Podoplanin overexpression in human mesothelioma cell lines enhances the tumorigenic phenotype. Oncol Rep 29 (3): 932-940.
58. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, Franzoso G, Carbone M,. 2006. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway,a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103 (27): 10397-10402.
59. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M,. 2010. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release,resultant inflammation. Proc Natl Acad Sci USA 107 (28): 12611-12616.
60. Yung S, Chan TM,. 2007. Mesothelial cells. Perit Dial Int 27: (Suppl 2): S110-S115.